AVITA Medical to Announce First Quarter 2025 Financial Results
AVITA Medical (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound company, has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, after U.S. market close. The company will host a conference call and webcast on the same day at 1:30 p.m. Pacific Time (May 9, 2025, 6:30 a.m. Australian Eastern Standard Time) to discuss financial performance and recent business highlights.
Investors can access the live webcast through the Events & Presentations section on AVITA Medical's website at ir.avitamedical.com. For telephone participation, advance registration is required to receive dial-in details and a personal PIN.
AVITA Medical (NASDAQ: RCEL, ASX: AVH), azienda leader nel settore delle terapie per ferite acute, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per giovedì 8 maggio 2025, dopo la chiusura del mercato statunitense. La società terrà una conference call e una webcast lo stesso giorno alle 13:30 ora del Pacifico (9 maggio 2025, 6:30 ora standard orientale australiana) per discutere delle performance finanziarie e degli ultimi sviluppi aziendali.
Gli investitori potranno seguire la diretta streaming tramite la sezione Eventi e Presentazioni sul sito web di AVITA Medical all'indirizzo ir.avitamedical.com. Per partecipare telefonicamente, è necessaria la registrazione anticipata per ricevere i dettagli di accesso e un PIN personale.
AVITA Medical (NASDAQ: RCEL, ASX: AVH), una empresa líder en terapias para heridas agudas, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el jueves 8 de mayo de 2025, después del cierre del mercado estadounidense. La compañía realizará una llamada conferencia y una transmisión en vivo ese mismo día a la 1:30 p.m. hora del Pacífico (9 de mayo de 2025, 6:30 a.m. hora estándar del este australiano) para analizar el desempeño financiero y los aspectos destacados recientes del negocio.
Los inversionistas podrán acceder a la transmisión en vivo a través de la sección Eventos y Presentaciones en el sitio web de AVITA Medical en ir.avitamedical.com. Para participar por teléfono, es necesario registrarse con anticipación para recibir los detalles de marcación y un PIN personal.
AVITA Medical (NASDAQ: RCEL, ASX: AVH)는 급성 상처 치료 분야의 선도 기업으로, 2025년 1분기 재무 실적 발표를 2025년 5월 8일 목요일 미국 시장 마감 후에 예정하고 있습니다. 회사는 같은 날 태평양 표준시 기준 오후 1시 30분(2025년 5월 9일 호주 동부 표준시 오전 6시 30분)에 재무 성과 및 최근 사업 하이라이트에 대해 논의하는 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다.
투자자들은 AVITA Medical 웹사이트 ir.avitamedical.com의 이벤트 및 프레젠테이션 섹션을 통해 실시간 웹캐스트에 접속할 수 있습니다. 전화 참여를 원할 경우, 사전 등록을 통해 다이얼인 정보와 개인 PIN을 받아야 합니다.
AVITA Medical (NASDAQ : RCEL, ASX : AVH), une entreprise leader dans les traitements des plaies aiguës, a programmé l’annonce de ses résultats financiers du premier trimestre 2025 pour le jeudi 8 mai 2025, après la clôture du marché américain. La société organisera une conférence téléphonique et une webdiffusion le même jour à 13h30 heure du Pacifique (9 mai 2025, 6h30 heure normale de l’Est australien) afin de discuter des performances financières et des faits marquants récents.
Les investisseurs peuvent accéder à la webdiffusion en direct via la section Événements et Présentations sur le site web d’AVITA Medical à l’adresse ir.avitamedical.com. Pour participer par téléphone, une inscription préalable est requise afin de recevoir les informations d’appel et un code PIN personnel.
AVITA Medical (NASDAQ: RCEL, ASX: AVH), ein führendes Unternehmen im Bereich der therapeutischen Behandlung akuter Wunden, hat die Veröffentlichung der Finanzergebnisse für das erste Quartal 2025 für Donnerstag, den 8. Mai 2025, nach Börsenschluss in den USA geplant. Das Unternehmen wird am selben Tag um 13:30 Uhr Pazifischer Zeit (9. Mai 2025, 6:30 Uhr Australische Oststandardzeit) eine Telefonkonferenz und einen Webcast abhalten, um die finanzielle Leistung und aktuelle Geschäftshighlights zu besprechen.
Investoren können den Live-Webcast über den Bereich „Events & Presentations“ auf der Website von AVITA Medical unter ir.avitamedical.com verfolgen. Für die telefonische Teilnahme ist eine vorherige Registrierung erforderlich, um die Einwahldaten und eine persönliche PIN zu erhalten.
- None.
- None.
VALENCIA, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound company delivering transformative solutions, today announced that it will report its first quarter 2025 financial results after the close of the U.S. financial markets on Thursday, May 8, 2025. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, May 9, 2025, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights.
The live webcast will be accessible under the Events & Presentations section of the AVITA Medical website at ir.avitamedical.com. To participate by telephone, please register in advance to receive dial-in details and a personal PIN using the following link: https://register-conf.media-server.com/register/BI88e9b0f5d021416f94e97d9729bf6cfa. A replay of the webcast will be available shortly after the live event on the Investor Relations website.
About AVITA Medical, Inc.
AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the FDA for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute both Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm®, a biosynthetic wound matrix.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns and full-thickness skin defects. The RECELL System, excluding RECELL GO®, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.
To learn more, visit www.avitamedical.com.
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
Investor & Media Contact: Jessica Ekeberg Phone +1-661-904-9269 investor@avitamedical.com media@avitamedical.com
FAQ
When will AVITA Medical (RCEL) release Q1 2025 earnings?
How can investors join AVITA Medical's (RCEL) Q1 2025 earnings call?
What time is AVITA Medical's (RCEL) Q1 2025 earnings call?
Where can I find the replay of AVITA Medical's (RCEL) Q1 2025 earnings call?
